For edoxaban, an oral reversible direct factor Xa inhibitor, a sub-analysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial, demonstrated comparable efficacy in stroke/SE prevention and a similar safety profile (in terms of major bleeding) to warfarin in patients with and without HF, regardless of HF severity [19]. This evidence concerns the gene F10 and hydrops fetalis.